Rankings
▼
Calendar
EVMN Q4 2024 Earnings — Evommune, Inc. Revenue & Financial Results | Market Cap Arena
EVMN
Evommune, Inc.
$319M
Q4 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
$0
Operating Income
-$19M
Net Income
-$18M
EPS (Diluted)
$-1.47
Cash Flow
Operating Cash Flow
-$22M
Free Cash Flow
-$22M
Stock-Based Comp.
$448,000
Balance Sheet
Total Assets
$76M
Total Liabilities
$220M
Stockholders' Equity
$48M
Cash & Equivalents
$16M
← FY 2024
All Quarters
Q1 2025 →